IL232386A0 - Preparations containing halophanate or halophanic acid and a substance that lowers urate and their uses - Google Patents

Preparations containing halophanate or halophanic acid and a substance that lowers urate and their uses

Info

Publication number
IL232386A0
IL232386A0 IL232386A IL23238614A IL232386A0 IL 232386 A0 IL232386 A0 IL 232386A0 IL 232386 A IL232386 A IL 232386A IL 23238614 A IL23238614 A IL 23238614A IL 232386 A0 IL232386 A0 IL 232386A0
Authority
IL
Israel
Prior art keywords
halofenate
urate
compositions
lowering agent
halofenic acid
Prior art date
Application number
IL232386A
Other languages
English (en)
Hebrew (he)
Original Assignee
Metabolex Inc
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc, Cymabay Therapeutics Inc filed Critical Metabolex Inc
Publication of IL232386A0 publication Critical patent/IL232386A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL232386A 2011-11-04 2014-04-30 Preparations containing halophanate or halophanic acid and a substance that lowers urate and their uses IL232386A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (fr) 2011-11-04 2011-11-04 Procédés de traitement de l'hyperuricémie chez des patients atteints de goutte, au moyen d'halofénate ou d'acide halofénique et d'un second agent de réduction d'urate

Publications (1)

Publication Number Publication Date
IL232386A0 true IL232386A0 (en) 2014-06-30

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232386A IL232386A0 (en) 2011-11-04 2014-04-30 Preparations containing halophanate or halophanic acid and a substance that lowers urate and their uses

Country Status (13)

Country Link
EP (1) EP2773336A4 (fr)
JP (1) JP6202633B2 (fr)
KR (1) KR20140121383A (fr)
CN (2) CN109908124A (fr)
AU (1) AU2011380507B2 (fr)
CA (1) CA2859686C (fr)
CL (1) CL2014001155A1 (fr)
IL (1) IL232386A0 (fr)
MX (1) MX357507B (fr)
NZ (1) NZ624708A (fr)
SG (1) SG11201402032RA (fr)
WO (1) WO2013066349A1 (fr)
ZA (1) ZA201403575B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836209A4 (fr) * 2012-04-13 2015-11-25 Cymabay Therapeutics Inc Méthode de traitement de l'hyperuricémie, faisant appel à l'halofénate ou à l'acide halofénique et à un agent anti-inflammatoire, chez les patients souffrant de goutte
JP6368756B2 (ja) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
CN108014108A (zh) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用
US11446317B2 (en) 2017-10-26 2022-09-20 Otsuka Pharmaceutical Co., Ltd. Inositol phosphate-containing composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
WO2011032175A1 (fr) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Formulations combinées de tranilast et d'allopurinol et procédés associées à celles-ci

Also Published As

Publication number Publication date
ZA201403575B (en) 2015-11-25
EP2773336A4 (fr) 2015-06-03
CN104066427A (zh) 2014-09-24
EP2773336A1 (fr) 2014-09-10
MX2014005400A (es) 2015-02-12
CA2859686C (fr) 2018-09-11
JP6202633B2 (ja) 2017-09-27
CL2014001155A1 (es) 2015-01-16
JP2014532758A (ja) 2014-12-08
MX357507B (es) 2018-07-12
NZ624708A (en) 2015-11-27
KR20140121383A (ko) 2014-10-15
AU2011380507B2 (en) 2017-06-15
CA2859686A1 (fr) 2013-05-10
SG11201402032RA (en) 2014-09-26
CN109908124A (zh) 2019-06-21
WO2013066349A1 (fr) 2013-05-10
AU2011380507A1 (en) 2014-05-29

Similar Documents

Publication Publication Date Title
HK1253692A1 (zh) 含有hdac抑制劑和環多醣的藥物組合物
IL250259A0 (en) Preparations containing ursolic acid or its derivative and their uses
AP3821A (en) Pesticidal compositions and processes related thereto
EP2646468A4 (fr) Compositions anti-ngf et leur utilisation
HK1195793A1 (zh) 結合藥物組合物及其用途
AP2013006890A0 (en) Pesticidal compositions and processes related thereto
ZA201209259B (en) Uses and compositions
EP2758183A4 (fr) Compositions biodégradables et leur utilisation
ZA201305749B (en) Pesticidal compositions and processes related thereof
HK1192152A1 (zh) 新型抗紅班活性劑和含相同的組合物
ZA201402321B (en) Compositions comprising salbutamol sulphate
SG10202112138QA (en) Compositions comprising peg and sulphate
GB201113770D0 (en) Novel compositions and uses thereof
ZA201402234B (en) Compositions comprising salbutamol sulphate
HK1200275A1 (en) Disinfectant compositions and uses thereof
EP2768909A4 (fr) Formulation d'encre et fabrication de celle-ci
EP2775831A4 (fr) Compositions pharmaceutiques et leurs utilisations
EP2753341A4 (fr) Compositions antimicrobiennes et utilisations associées
EP2668044A4 (fr) Compositions et leur utilisation
IL232386A0 (en) Preparations containing halophanate or halophanic acid and a substance that lowers urate and their uses
IL228403A0 (en) Preparations containing anti-influenza antibodies and osetamivir and their uses
PL2648715T3 (pl) Mieszaniny karnozyny-kwasu hialuronowego i ich zastosowanie
GB201106357D0 (en) Composition and uses thereof
EP2542059A4 (fr) Compositions comportant de l'acide myristique et leurs utilisations
GB201005826D0 (en) New compositions and their use